ArticleJBMR plus2026
Differential effects of romosozumab across central and peripheral skeletal sites: a prospective DXA and HR-pQCT study in high-risk postmenopausal osteoporosis.
Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRomosozumab is known to markedly increase areal BMD (aBMD) at the LS and proximal femur assessed by DXA; however, its effects on peripheral volumetric BMD (vBMD) and bone microarchitecture measured by HR-pQCT remain incompletely characterized in postmenopausal women at very high fracture risk. MATERIALS AND
methodsIn this single-center, prospective longitudinal observational study, postmenopausal women with primary osteoporosis and a history of fragility fractures received romosozumab for 12 mo. DXA (LS, proximal femur, and radius) and HR-pQCT (distal radius and tibia) were performed at baseline and at 6 and 12 mo.
resultsTwenty-five patients were enrolled; 22 completed 12 mo and were analyzed. LS (L1-L4) aBMD increased by 18.0% at 6 mo and 24.4% at 12 mo (both DISCUSSION: These findings suggest that 12 mo of romosozumab treatment resulted in marked increases in central aBMD at the LS and proximal femur by DXA, while effects on peripheral aBMD, vBMD, and bone microarchitecture at the distal radius and tibia assessed by DXA and HR-pQCT were limited, suggesting site-specific skeletal responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.